Revenue and Profitability - Revenue for Q1 2025 was CNY 24,286,732.74, a decrease of 68.09% compared to CNY 76,119,952.75 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,578,952.62, down 85.25% from CNY 10,707,388.40 year-on-year[5] - Basic and diluted earnings per share were CNY 0.0161, down 85.00% from CNY 0.1073 in the same period last year[5] - The net profit for the current period is 1,578,952.62, a significant decrease from 10,707,388.40 in the previous period, representing a decline of approximately 85.2%[20] - The operating profit for the current period is 1,538,872.30, down from 10,618,920.79 in the previous period, indicating a decrease of about 85.5%[20] - The total comprehensive income for the current period is 1,578,952.62, down from 10,707,388.40 in the previous period, reflecting a decrease of about 85.2%[20] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 15,090,975.28, a decline of 140.24% compared to CNY 37,498,382.94 in the previous year[5] - Cash flow from operating activities shows a net outflow of -15,090,975.28, compared to a net inflow of 37,498,382.94 in the previous period, reflecting a substantial change in cash flow dynamics[22] - Total cash and cash equivalents at the end of the period stand at 486,663,948.02, down from 694,758,375.54 at the end of the previous period, a decrease of approximately 30%[23] - The company reported cash inflows from investment activities of 81,292,444.44, while cash outflows totaled 195,512,870.38, resulting in a net cash outflow of -114,220,425.94 from investment activities[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,957,273,279.76, an increase of 0.53% from CNY 1,946,989,678.97 at the end of the previous year[5] - The total liabilities at the end of the period are CNY 709,642,530.16, an increase of 7.2% from CNY 661,987,013.29 at the beginning of the period[17] - The accounts receivable decreased to CNY 638,636,200.10, down 9.5% from CNY 705,456,938.63 at the beginning of the period[15] - The inventory increased to CNY 254,737,658.66, up 24.7% from CNY 204,203,626.98 at the beginning of the period[15] Operational Performance - The total operating revenue for the current period is CNY 24,286,732.74, a decrease of 68.1% compared to CNY 76,119,952.75 in the previous period[19] - The total operating costs for the current period amount to CNY 33,730,745.31, down 56.5% from CNY 77,757,539.66 in the previous period[19] - The company experienced a significant reduction in cash inflows from sales of goods and services, which totaled 138,755,526.69, compared to 257,093,414.86 in the previous period, a decline of approximately 46.0%[22] - The company reported a decrease in operating cash inflows, totaling 147,940,993.16, down from 269,434,763.64 in the previous period, indicating a decline of about 45.0%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,455[9] - The company has a scheduled release of restricted shares for major shareholders on January 27, 2025, which may impact future stock performance[13] Financing Activities - Short-term borrowings rose by 32.26% year-on-year, primarily due to an increase in working capital loans[10] - The company raised 96,000,000.00 in borrowings during the current period, compared to 75,102,630.93 in the previous period, indicating an increase of approximately 28% in financing activities[23] Research and Development - The company plans to continue focusing on research and development, with R&D expenses amounting to CNY 4,280,463.49 for the current period[19] Inventory Management - Inventory shares increased by 167.17% year-on-year, attributed to the implementation of share buybacks[10] - Prepayments increased by 92.56% year-on-year, mainly due to an increase in procurement prepayments[10] Investment Income - Investment income decreased by 100% year-on-year, as there were no interest earnings from structured deposits in the current period[10]
港通医疗(301515) - 2025 Q1 - 季度财报